Tags

Type your tag names separated by a space and hit enter

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Pediatr Infect Dis J. 2009 Apr; 28(4 Suppl):S77-88.PI

Abstract

BACKGROUND

Immunogenicity of the candidate 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was assessed when coadministered with other routine pediatric vaccines including different Neisseria meningitidis serogroup C conjugate vaccines.

METHODS

One thousand five hundred forty-eight healthy infants received, according to a balanced (1:1:1:1) randomization, either PHiD-CV coadministered with (1) DTPa-HBV-IPV/Hib (Infanrix hexa) and MenC-CRM (Meningitec), (2) DTPa-HBV-IPV/Hib and MenC-TT (NeisVac-C), or (3) DTPa-HBV-IPV (Infanrix penta/Pediarix) and Hib-MenC-TT (Menitorix); or 7vCRM (Prevenar/Prevnar) coadministered with DTPa-HBV-IPV and Hib-MenC-TT at 2-4-6 months of age with a booster dose at 11-18 months. Serotype-specific pneumococcal responses were measured by 22F-inhibition ELISA and opsonophagocytic (OPA) assay.

RESULTS

In all 3 coadministration groups, PHiD-CV was immunogenic for each of the 10 pneumococcal vaccine serotypes as assessed by post-primary and post-booster antibody ELISA and OPA responses. When coadministered with DTPa-HBV-IPV, Hib, and MenC antigens, PHiD-CV responses after the third primary dose were within the same range as 7vCRM responses in terms of the percentage of subjects achieving an ELISA antibody concentration >or=0.2 microg/mL for all common vaccine serotypes (over 92% of subjects) except for serotype 6B (at least 87% of subjects). ELISA and OPA immune responses were also evident after the second primary doses of PHiD-CV or 7vCRM vaccine, although antibody levels were below that achieved after 3 primary doses, particularly for serotypes 6B and 23F. The kinetics of the immune responses from after the second dose to after the booster dose were similar for most of the serotypes in both PHiD-CV and 7vCRM groups.

CONCLUSIONS

PHiD-CV was immunogenic when coadministered with other routine pediatric vaccines including MenC conjugate vaccines.

Authors+Show Affiliations

University School of Medical Sciences & Regional Medical Center for Mother and Child, Poznan, Poland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19325450

Citation

Wysocki, Jacek, et al. "Immunogenicity of the 10-valent Pneumococcal Non-typeable Haemophilus Influenzae Protein D Conjugate Vaccine (PHiD-CV) when Coadministered With Different Neisseria Meningitidis Serogroup C Conjugate Vaccines." The Pediatric Infectious Disease Journal, vol. 28, no. 4 Suppl, 2009, pp. S77-88.
Wysocki J, Tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J. 2009;28(4 Suppl):S77-88.
Wysocki, J., Tejedor, J. C., Grunert, D., Konior, R., Garcia-Sicilia, J., Knuf, M., Bernard, L., Dieussaert, I., & Schuerman, L. (2009). Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. The Pediatric Infectious Disease Journal, 28(4 Suppl), S77-88. https://doi.org/10.1097/INF.0b013e318199f609
Wysocki J, et al. Immunogenicity of the 10-valent Pneumococcal Non-typeable Haemophilus Influenzae Protein D Conjugate Vaccine (PHiD-CV) when Coadministered With Different Neisseria Meningitidis Serogroup C Conjugate Vaccines. Pediatr Infect Dis J. 2009;28(4 Suppl):S77-88. PubMed PMID: 19325450.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. AU - Wysocki,Jacek, AU - Tejedor,Juan C, AU - Grunert,Dutlef, AU - Konior,Ryszard, AU - Garcia-Sicilia,Jose, AU - Knuf,Markus, AU - Bernard,Laurence, AU - Dieussaert,Ilse, AU - Schuerman,Lode, PY - 2009/3/28/entrez PY - 2009/4/11/pubmed PY - 2009/5/19/medline SP - S77 EP - 88 JF - The Pediatric infectious disease journal JO - Pediatr Infect Dis J VL - 28 IS - 4 Suppl N2 - BACKGROUND: Immunogenicity of the candidate 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was assessed when coadministered with other routine pediatric vaccines including different Neisseria meningitidis serogroup C conjugate vaccines. METHODS: One thousand five hundred forty-eight healthy infants received, according to a balanced (1:1:1:1) randomization, either PHiD-CV coadministered with (1) DTPa-HBV-IPV/Hib (Infanrix hexa) and MenC-CRM (Meningitec), (2) DTPa-HBV-IPV/Hib and MenC-TT (NeisVac-C), or (3) DTPa-HBV-IPV (Infanrix penta/Pediarix) and Hib-MenC-TT (Menitorix); or 7vCRM (Prevenar/Prevnar) coadministered with DTPa-HBV-IPV and Hib-MenC-TT at 2-4-6 months of age with a booster dose at 11-18 months. Serotype-specific pneumococcal responses were measured by 22F-inhibition ELISA and opsonophagocytic (OPA) assay. RESULTS: In all 3 coadministration groups, PHiD-CV was immunogenic for each of the 10 pneumococcal vaccine serotypes as assessed by post-primary and post-booster antibody ELISA and OPA responses. When coadministered with DTPa-HBV-IPV, Hib, and MenC antigens, PHiD-CV responses after the third primary dose were within the same range as 7vCRM responses in terms of the percentage of subjects achieving an ELISA antibody concentration >or=0.2 microg/mL for all common vaccine serotypes (over 92% of subjects) except for serotype 6B (at least 87% of subjects). ELISA and OPA immune responses were also evident after the second primary doses of PHiD-CV or 7vCRM vaccine, although antibody levels were below that achieved after 3 primary doses, particularly for serotypes 6B and 23F. The kinetics of the immune responses from after the second dose to after the booster dose were similar for most of the serotypes in both PHiD-CV and 7vCRM groups. CONCLUSIONS: PHiD-CV was immunogenic when coadministered with other routine pediatric vaccines including MenC conjugate vaccines. SN - 0891-3668 UR - https://www.unboundmedicine.com/medline/citation/19325450/Immunogenicity_of_the_10_valent_pneumococcal_non_typeable_Haemophilus_influenzae_protein_D_conjugate_vaccine__PHiD_CV__when_coadministered_with_different_neisseria_meningitidis_serogroup_C_conjugate_vaccines_ L2 - https://doi.org/10.1097/INF.0b013e318199f609 DB - PRIME DP - Unbound Medicine ER -